Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Sumitomo Charts Revival Plan, Eyes 250 Billion Yen with 3 Key Meds by FY2027
After two straight years of losses, Sumitomo Pharma is back in the black - and now ready for a “reboot.” The company on May 13 unveiled its new three-year plan to resurge as a strong pharma player, targeting sizable growth…
To read the full story
Related Article
- Sumitomo Notches Record Profit on Strong North America Growth
May 14, 2026
- Sumitomo Regains Growth Momentum, Eyes 350 Billion Yen from 2 Key Drugs in FY2028
March 3, 2026
- Sumitomo Pharma Sees iPSC Therapy as Potential US$1 Billion Global Product
February 18, 2026
- Sumitomo Flags Diabetes Pipeline Gap as Key Strategic Issue: CEO
February 2, 2026
- Sumitomo within Striking Distance of 250-Billion-Yen Goal for 3 Key Drugs
November 4, 2025
BUSINESS
- Nipro Pharma Recalls Topical Drugs over Long-Running Manufacturing Deviations
July 16, 2026
- Ferring’s Adstiladrin, Boehringer’s Jascayd Hit Market; Haizexin Due July 28
July 16, 2026
- JCR to File DMD Drug Givinostat in Japan by End-2026
July 16, 2026
- FRONTEO, Daiichi Sankyo Build AI Model to Analyze Toxicity Reports
July 15, 2026
- Cell Resources Launches Umbilical Cord- and Amnion-Derived MSCs
July 15, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…